High endoplasmic reticulum activity renders Multiple myeloma cells hypersensitive to mitochondrial inhibitors

Metin Kurtoglu, Katherine Philips, Huaping Liu, Lawrence H. Boise, Theodore Lampidis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Multiple myeloma (MM) cells continuously secrete large amounts of immunoglobulins that are folded in the endoplasmic reticulum (ER) whose function depend on the Ca2+ concentration inside its lumen. Recently, it was shown that the ER membrane leaks Ca2+ that is captured and delivered back by mitochondria in order to prevent its loss. Thus, we hypothesized that the highly active and abundant ER in MM cells results in greater Ca 2+-regulation by mitochondria which would render them sensitive to mitochondrial inhibitors. Here, we indeed find that Ca2+ leak is greater in 3 MM, when compared to 2 B-cell leukemia cell lines. Moreover, this greater leak in MM cells is associated with hypersensitivity to various mitochondrial inhibitors, including CCCP. Consistent with our hypothesis, CCCP is more potent in inducing the unfolded protein response marker, CHOP/GADD153 in MM versus B-cell leukemia lines. Additionally, MM cells are found to be significantly more sensitive to clinically used fenofibrate and troglitazone, both of which were recently shown to have inhibitory effects on mitochondrial function. Overall, our results demonstrate that the unusually high ER activity in MM cells may be exploited for therapeutic benefit through the use of mitochondrial inhibitors including troglitazone and fenofibrate.

Original languageEnglish
Pages (from-to)129-140
Number of pages12
JournalCancer Chemotherapy and Pharmacology
Volume66
Issue number1
DOIs
StatePublished - May 1 2010

Fingerprint

troglitazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone
Multiple Myeloma
Endoplasmic Reticulum
Fenofibrate
Mitochondria
Cells
B-Cell Leukemia
Immunoglobulins
Membranes
Unfolded Protein Response
Cell Line
Proteins
Hypersensitivity

Keywords

  • Calcium
  • Fenofibrate
  • Mitochondria
  • Multiple myeloma
  • Troglitazone
  • Unfolded protein response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

High endoplasmic reticulum activity renders Multiple myeloma cells hypersensitive to mitochondrial inhibitors. / Kurtoglu, Metin; Philips, Katherine; Liu, Huaping; Boise, Lawrence H.; Lampidis, Theodore.

In: Cancer Chemotherapy and Pharmacology, Vol. 66, No. 1, 01.05.2010, p. 129-140.

Research output: Contribution to journalArticle

Kurtoglu, Metin ; Philips, Katherine ; Liu, Huaping ; Boise, Lawrence H. ; Lampidis, Theodore. / High endoplasmic reticulum activity renders Multiple myeloma cells hypersensitive to mitochondrial inhibitors. In: Cancer Chemotherapy and Pharmacology. 2010 ; Vol. 66, No. 1. pp. 129-140.
@article{7765e0e154d549349d584089b2cfb041,
title = "High endoplasmic reticulum activity renders Multiple myeloma cells hypersensitive to mitochondrial inhibitors",
abstract = "Multiple myeloma (MM) cells continuously secrete large amounts of immunoglobulins that are folded in the endoplasmic reticulum (ER) whose function depend on the Ca2+ concentration inside its lumen. Recently, it was shown that the ER membrane leaks Ca2+ that is captured and delivered back by mitochondria in order to prevent its loss. Thus, we hypothesized that the highly active and abundant ER in MM cells results in greater Ca 2+-regulation by mitochondria which would render them sensitive to mitochondrial inhibitors. Here, we indeed find that Ca2+ leak is greater in 3 MM, when compared to 2 B-cell leukemia cell lines. Moreover, this greater leak in MM cells is associated with hypersensitivity to various mitochondrial inhibitors, including CCCP. Consistent with our hypothesis, CCCP is more potent in inducing the unfolded protein response marker, CHOP/GADD153 in MM versus B-cell leukemia lines. Additionally, MM cells are found to be significantly more sensitive to clinically used fenofibrate and troglitazone, both of which were recently shown to have inhibitory effects on mitochondrial function. Overall, our results demonstrate that the unusually high ER activity in MM cells may be exploited for therapeutic benefit through the use of mitochondrial inhibitors including troglitazone and fenofibrate.",
keywords = "Calcium, Fenofibrate, Mitochondria, Multiple myeloma, Troglitazone, Unfolded protein response",
author = "Metin Kurtoglu and Katherine Philips and Huaping Liu and Boise, {Lawrence H.} and Theodore Lampidis",
year = "2010",
month = "5",
day = "1",
doi = "10.1007/s00280-009-1143-1",
language = "English",
volume = "66",
pages = "129--140",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - High endoplasmic reticulum activity renders Multiple myeloma cells hypersensitive to mitochondrial inhibitors

AU - Kurtoglu, Metin

AU - Philips, Katherine

AU - Liu, Huaping

AU - Boise, Lawrence H.

AU - Lampidis, Theodore

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Multiple myeloma (MM) cells continuously secrete large amounts of immunoglobulins that are folded in the endoplasmic reticulum (ER) whose function depend on the Ca2+ concentration inside its lumen. Recently, it was shown that the ER membrane leaks Ca2+ that is captured and delivered back by mitochondria in order to prevent its loss. Thus, we hypothesized that the highly active and abundant ER in MM cells results in greater Ca 2+-regulation by mitochondria which would render them sensitive to mitochondrial inhibitors. Here, we indeed find that Ca2+ leak is greater in 3 MM, when compared to 2 B-cell leukemia cell lines. Moreover, this greater leak in MM cells is associated with hypersensitivity to various mitochondrial inhibitors, including CCCP. Consistent with our hypothesis, CCCP is more potent in inducing the unfolded protein response marker, CHOP/GADD153 in MM versus B-cell leukemia lines. Additionally, MM cells are found to be significantly more sensitive to clinically used fenofibrate and troglitazone, both of which were recently shown to have inhibitory effects on mitochondrial function. Overall, our results demonstrate that the unusually high ER activity in MM cells may be exploited for therapeutic benefit through the use of mitochondrial inhibitors including troglitazone and fenofibrate.

AB - Multiple myeloma (MM) cells continuously secrete large amounts of immunoglobulins that are folded in the endoplasmic reticulum (ER) whose function depend on the Ca2+ concentration inside its lumen. Recently, it was shown that the ER membrane leaks Ca2+ that is captured and delivered back by mitochondria in order to prevent its loss. Thus, we hypothesized that the highly active and abundant ER in MM cells results in greater Ca 2+-regulation by mitochondria which would render them sensitive to mitochondrial inhibitors. Here, we indeed find that Ca2+ leak is greater in 3 MM, when compared to 2 B-cell leukemia cell lines. Moreover, this greater leak in MM cells is associated with hypersensitivity to various mitochondrial inhibitors, including CCCP. Consistent with our hypothesis, CCCP is more potent in inducing the unfolded protein response marker, CHOP/GADD153 in MM versus B-cell leukemia lines. Additionally, MM cells are found to be significantly more sensitive to clinically used fenofibrate and troglitazone, both of which were recently shown to have inhibitory effects on mitochondrial function. Overall, our results demonstrate that the unusually high ER activity in MM cells may be exploited for therapeutic benefit through the use of mitochondrial inhibitors including troglitazone and fenofibrate.

KW - Calcium

KW - Fenofibrate

KW - Mitochondria

KW - Multiple myeloma

KW - Troglitazone

KW - Unfolded protein response

UR - http://www.scopus.com/inward/record.url?scp=77951883873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951883873&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1143-1

DO - 10.1007/s00280-009-1143-1

M3 - Article

C2 - 19779717

AN - SCOPUS:77951883873

VL - 66

SP - 129

EP - 140

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -